HGF and gastric cancer: Two monoclonal antibodies, Rilotumumab (an anti-HGF antibody) and Onartuzumab (an anti-MET antibody) were tested in clinical trials in GC: early reports [48,49] suggested that MET expression could serve as a predictive biomarker for anti-MET directed therapies, but in both phase III clinical trials evaluating Onartuzumab and Rilotumumab, the results were negative.